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Abstract
Background: Laparoscopic ventral mesh rectopexy (LVMR) is an established treatment for external full-thickness
rectal prolapse. However, its clinical efficacy in patients with internal prolapse is uncertain due to the lack of high-
quality evidence.
Methods: An individual level, stepped-wedge randomised trial has been designed to allow observer-blinded data
comparisons between patients awaiting LVMR with those who have undergone surgery. Adults with symptomatic
internal rectal prolapse, unresponsive to prior conservative management, will be eligible to participate. They will be
randomised to three arms with different delays before surgery (0, 12 and 24 weeks). Efficacy outcome data will be
collected at equally stepped time points (12, 24, 36 and 48 weeks). The primary objective is to determine clinical
efficacy of LVMR compared to controls with reduction in the Patient Assessment of Constipation Quality of Life
(PAC-QOL) at 24 weeks serving as the primary outcome. Secondary objectives are to determine: (1) the clinical
effectiveness of LVMR to 48 weeks to a maximum of 72 weeks; (2) pre-operative determinants of outcome; (3)
relevant health economics for LVMR; (4) qualitative evaluation of patient and health professional experience of
LVMR and (5) 30-day morbidity and mortality rates.
Discussion: An individual-level, stepped-wedge, randomised trial serves the purpose of providing an untreated
comparison for the active treatment group, while at the same time allowing the waiting-listed participants an
opportunity to obtain the intervention at a later date. In keeping with the basic ethical tenets of this design, the
average waiting time for LVMR (12 weeks) will be shorter than that for routine services (24 weeks).
Trial registration: ISRCTN registry, ISRCTN11747152. Registered on 30 September 2015. The trial was prospectively
registered (first patient enrolled on 21 March 2016).
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Background
Burden of disease
Constipation is common in adults and children and
up to 20% of the population report this symptom de-
pending on definitions used (2–28% adults; 0.7–30%
children) [1–3], with a higher prevalence in women
[1, 4, 5] and the elderly [6, 7]. Chronic constipation
(CC), usually defined as more than 6 months of
symptoms, is less common [8] but results in 0.5 mil-
lion UK General Practitioner (GP) consultations per
annum. A proportion of the population suffers symp-
toms that are both chronic and more disabling (prob-
ably about 1–2% of the population) [9]. Such patients,
who are very frequently female [10], are usually re-
ferred to secondary care with many progressing to
tertiary specialist investigation. Patient dissatisfaction
is high in this group; nearly 80% feel that laxative
therapy is unsatisfactory [11] and the effect of symp-
toms on measured quality of life (QOL) is significant
[12]. CC consumes significant healthcare resources. In
the USA in 2012, a primary complaint of constipation
was responsible for 3.2 million physician visits [13]
resulting in (direct and indirect) costs of US$1.7 bil-
lion. In the UK, it is estimated 10% of district nursing
time is spent on constipation [14] and the annual
spend on laxatives exceeds £80 million, with a cost of
£17.4 million for prescriptions in 2012 (Health and
Social Care Information Centre, 2013) [15].
Pathophysiological basis of chronic constipation
The act of defaecation is dependent on the coordinated
functions of the colon, rectum and anus. Considering
the complexity of neuromuscular (sensory and motor)
functions required to achieve planned, conscious, and
effective defaecation [16], it is no surprise that distur-
bances to perceived “normal” function occur com-
monly at all stages of life. Clinically, such problems
commonly lead to symptoms of obstructed defaecation
(e.g. straining; incomplete, unsuccessful or painful
evacuation; bowel infrequency and abdominal pain and
bloating). After exclusion of a multitude of secondary
causes (obstructing colonic lesions, neurological, meta-
bolic and endocrine disorders), the pathophysiology of
CC can broadly be divided into problems of colonic
contractile activity and thus stool transit and problems
of the pelvic floor. Thus, with specialist radio-
physiological investigations (hereafter referred to as
INVEST in this protocol), patients may be divided into
those who have slow colonic transit, evacuation dis-
order, both or neither (no abnormality found with
current tests). Evacuation disorders can be then subdi-
vided into those in which a structurally significant
pelvic-floor abnormality is evident, e.g. rectocele or
internal prolapse (intussusception), and those in which
there is a dynamic failure of evacuation without struc-
tural abnormality, most commonly termed functional
defaecation disorder (FDD).
Chronic constipation management overview
Management of CC is a major problem due to its high
prevalence and lack of widespread specialist expertise. In
general, a step-wise approach is undertaken, with first-
line conservative treatment such as lifestyle advice and
laxatives (primary care) followed by nurse-led bowel re-
training programmes, sometimes including focused bio-
feedback and psychosocial support (secondary/tertiary
care). Although these treatments may improve symp-
toms in more than half of patients, they are very poorly
standardised in the UK and are not universally success-
ful. Patients with intractable symptoms and impaired
QOL may subsequently be offered a range of costly, irre-
versible surgical interventions with unpredictable results
[17, 18], sometimes resulting in major adverse events or
a permanent stoma.
Overall rationale for the CapaCiTY programme
The current trial forms part of a National Institute for
Health Research (NIHR)-funded programme (PGfAR, RP-
PG-0612-20001). This programme aims to develop the evi-
dence base for the management of CC in adults, which is
currently lacking. This is in contrast to the management of
CC in children for which National Institute for Health and
Care Excellence (NICE) guidance has been recently pub-
lished (https://www.nice.org.uk/guidance/cg99) [19, 20],
and for adults with faecal incontinence (http://pathways.ni-
ce.org.uk/pathways/faecal-incontinence). Thus there are
considerable variations in practice, particularly in specialist
services. With a number of new drugs gaining or seeking
National Health Service (NHS) approval [21–24] and tech-
nologies at a horizon scanning stage [17, 25–27], it is
timely that the currently limited evidence base is developed
for resource-constrained NHS providers to have confi-
dence that new and sometimes expensive investigations
and therapies are appropriate and cost-effective. A cost-
conscious pathway of care may help reduce healthcare ex-
penditures by appropriately sequencing the care provided,
while targeting more expensive therapies at those most
likely to benefit. Such data will inform the development
and commissioning of integrated care pathways. An over-
view of the CapaCiTY programme is provided as a scheme
(see Additional file 1) and includes a series of interlinked
studies that answer the important questions for patient
care. A rolling programme of national recruitment will
provide a large cohort of well-defined patients for three
subsequent studies over 5 years. The focus will be on gen-
erating real-life evidence from pragmatic studies that will
provide valid clinical outcome measures, and address
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patient acceptability and cost. Armed with such data it will
be possible to develop an NHS management algorithm for
CC, which will meet patient, clinician and policy aims.
Specific clinical background to the trial of laparoscopic
ventral mesh rectopexy (LVMR)
In most UK practices, patients are first referred to spe-
cialist nurses for a variety of nurse-led behavioural
interventions to improve defaecatory function. A range
of cohort studies [28], randomized controlled trials
(RCTs) [29–34], reviews [35], guidelines [36], a meta-
analysis [37] and a Cochrane review [38] attest to the
general success of this approach. Specific methodo-
logical issues are being addressed by CapaCiTY study 1.
Patients failing behavioural interventions may progress
to anal irrigation (CapaCiTY study 2). However despite
these approaches, some patients will have persistent
intractable symptoms.
When non-surgical therapies fail, a decision must be
made whether to offer surgical intervention. Decision-
making is greatly influenced by local expertise,
commissioning and personal enthusiasm for particular
interventions [17, 18, 39], balanced against poor re-
sults in some patients [17]. Currently, there is thus
large and difficult-to-justify variation in surgical prac-
tice according to need and type of procedure. The
need to reduce variations in practice, based on avail-
able evidence, has been a perpetual theme of recent
national speciality group discussions [40] with various
initiatives proposed. A Multidisciplinary Decision
Team (MDT), incorporating expertise from nurses,
gastroenterologists, urogynaecologists, colorectal sur-
geons and psychologists to promote appreciation of
the whole pelvic floor (bladder, vagina, uterus and
bowel), could reduce the potential for inadequately-
informed and potentially harmful interventions in
poor surgical candidates [17], but the utility of this
approach has not been formally tested. Further, there
are few data on outcomes in well-characterised patient
cohorts or rational criteria for patient selection.
In practice, there are few pelvic-floor procedures that
are commonly employed in patients with CC, these be-
ing forms of rectopexy and rectocele repair in conjunc-
tion with urogynaecological approaches to other organ
prolapse [41]. Other procedures are only occasionally
performed in highly selected patients (e.g. colectomy/ile-
ostomy [18]), or should only be performed on a research
protocol basis (e.g. stapled transanal resection [36]) or
are subject to specialist commissioning approval (e.g.
sacral nerve stimulation [25, 27]).
LVMR is established as a treatment for external full-
thickness rectal prolapse [42–44] but is now being
widely performed internationally (including in many
centres in the UK) on large numbers of patients with
defaecatory problems concomitant with evidence of
pelvic-floor weakness - mainly rectocele and intussus-
ception [45–52]. The evidence needs for LVMR relate
to the following observations:
1. Patient selection:
– Rectocele and intussusception are present in at
least 40% of asymptomatic women, detection
depends significantly on method of assessment
[53, 54] and they frequently co-exist [55].
– The evident structural abnormality often belies a
complex multifactorial problem with several
contributing types of aetiology that cannot be
addressed by surgery alone [56].
– Structural correction (by a variety of approaches)
often poorly correlates with functional outcomes
[57–59].
2. Lack of trial evidence of efficacy:
– Evidence is based solely on short-term
observational data obtained in the most part
from individual expert case series [51, 60–62]
and to some extent by evolving patient
registries (populated by the same experts).
– Outcomes have generally been based on poorly
validated measures (e.g. patient global rating
scales [63]) and some bespoke summative scores
(e.g. obstructive defecation score [ODS] [45, 64]),
which were originally developed to show the
benefit of surgery [65, 66].
– There is concern that objectively determined
long-term outcomes of LVMR using validated
measures will not match those from enthusiastically
driven case series (as observed for numerous
other surgical procedures with the intent of
addressing CC) [17].
3. Risk:
– While early data show that LVMR is relatively
safe from immediate complications, it is
acknowledged that the placement of a mesh in
the pelvis is a high risk strategy due to
problems of migration, infection and erosion
[67]. The use of mesh placed trans-vaginally
has now led to class actions in all states of the USA
amounting to billions of dollars of law-suits (http://
www.drugwatch.com/transvaginal-mesh/law-
suit.php). Several countries (including Scotland)
(http://www.bbc.co.uk/news/uk-scotland-scotland-
politics-27884794) have suspended its use on this
basis. While placement of mesh trans-abdominally
is recognised to be safer (no exposure to vaginal
bacterial flora), and biological mesh may reduce
this complication (compared to synthetic mesh)
[68–70], there are still reported morbidity rates in
the 1–2% range [70, 71].
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– As with all other pelvic floor operations, some
patients may be made functionally worse by
surgery due to worsening of evacuation problems,
new problems of incontinence caused by altered
pelvic floor dynamics [72] and chronic pelvic pain
or dyspareunia [70]. Such problems are then very
difficult to correct by any method.
Such is the debate on LVMR that almost all inter-
national coloproctology meetings have whole sessions
dedicated to its discussion (especially the issue of mesh
complications); a recent consensus report has also been
published [73]. It is clear that while these complications
may be limited by good technique and perhaps choice of
mesh, they will not be eradicated. Thus, it can be argued
that the future of LVMR depends not on the very small
observed differences in long-term mesh complications
(e.g. 1.0–2.0% of patients) but on a fundamental evalu-
ation of whether the procedure is actually clinically
beneficial, i.e. whether these complication rates would
be deemed acceptable (provided patients are consented
to the risk) if the patient benefit was sufficiently large.
The aim of the proposed trial is to address this know-
ledge gap.
Specific study rationale
The overall rationale is to address the main objectives
(see below) within a controlled trial. We have used a
stepped-wedge, randomised trial design which permits
observer-masked data comparisons between patients
awaiting intervention with those who have undergone
surgery. Contrary to most stepped-wedge trials individ-
ual patients are randomised rather than clustered. In
brief (more detail below), eligible participants based on
clinical evaluation and radio-physiological investigations
(INVEST) will be randomised to three arms with differ-
ent lengths of delay before surgery (see Additional file 2).
In all arms there will be a period of 4 weeks post-
eligibility to arrange the logistics of surgery (time (T)–4
weeks to T0) and ensure that patients have returned to
their normal life routine after various assessments.
LVMR will be performed at T0 in group I; T12 (12
weeks) in group II and T24 (24 weeks) in group III. Un-
avoidably, participants will be aware when surgery is
undertaken: this, however, fortuitously meets the as-
sumptions of the stepped-wedge design, i.e. no effect of
treatment is expected until surgery has been performed.
Efficacy outcome data will be collected at equally
stepped time points (T0, 12, 24, 36 and 48 weeks).
This is, in effect, a modification of a standard, parallel-
arm, wait-list control design, but with several advantages.
First, a stepped-wedge design is more efficient and thus
improves recruitment feasibility (the bane of nearly all
surgical trials). Despite the multicentre approach of this
study, the problems of recruitment cannot be underesti-
mated. Simulation demonstrates that a parallel-arm design
requires a much larger sample size than that proposed for
the current study at the same power. Secondly, the trial
design means that there is only a one in three chance
(rather than one in two for a parallel arm) of waiting 6
months for surgery, which is more acceptable to patients.
Risks and benefits of participation
The risks of trial participation are considered very low
over and above standard surgical risks. The intervention
proposed is already offered to patients in specialist cen-
tres throughout the UK and internationally. The only
difference conferred by participation is that the interven-
tion will be randomly allocated by time and very care-
fully assessed. CC is a chronic condition (especially by
the time conservative treatments have failed) and thus
allocation to waiting times of up to 24 weeks poses no
clinical risk. Radio-physiological tests (INVEST) are
required to select patients with appropriate structural
pelvic-floor problems for surgery. These would be per-
formed in routine clinical practice in all patients under-
going LVMR and will also be mandated for the trial
using specified techniques and equipment. While this
may lead to slight variance from normal practice, the
fundamental tests and their safety remain unchanged.
Such tests have been performed daily in most specialist
centres for up to 30 years without any recorded compli-
cation (Barts Health experience is over 10,000 patients).
A small ionising radiation dose is required for two tests
(covered below). A number of questionnaires contain
personal questions about bowel problems and the effect
of these on QOL and psycho-behavioural functioning;
however, all have been used in studies of similar patients
previously. The design of the study requires data collec-
tion at time points additional to those required for the
analysis of the primary and secondary endpoints. How-
ever, this streamlines the logistics and management of
the study participants through the course of the study
whilst ensuring blinding is maintained and eliminating
observer bias. This small additional burden on partici-
pants has been carefully balanced against the obvious
benefits of the design and efficiencies of sample size
gained, reducing the overall number of participants
required to undergo surgery.
The benefits of participation are that patients will
receive a very high standard of surgery (the most experi-
enced UK surgeons will be participating). Further, by de-
sign, the fidelity of surgical technique will be standardised
and tightly scrutinised (including by preceptorship and
mentorship if required); they will also receive a high
standard of monitored care as a consequence of the
detailed protocol.
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Design/methods
This is a stepped-wedge, randomised trial of LVMR in
adults with chronic constipation (n = 114), which follows
the “Standard Protocol Items: Recommendations for Inter-
ventional Trials” (SPIRIT) guidelines (see Additional file 3).
Participants will be randomized to three equal arms
(n = 38) with different lengths of delay before surgery.
LVMR will be performed at T0 in group I; T12 (12
weeks) in group II and at T24 (24 weeks) in group III.
Trial objectives and endpoints
Primary objective
The primary objective is to determine the clinical effi-
cacy of LVMR compared to controls at short-term follow
up (24 weeks).
Secondary objectives
The secondary objectives are to:
1. Determine the clinical effectiveness of LVMR in the
medium term (to 48 weeks to a maximum of 72 weeks)
2. Determine pre-operative determinants of the
outcome
3. Determine relevant health economics for LVMR
4. Qualitatively evaluate patient and health professional
experience of LVMR
5. Assess 30-day morbidity and mortality rates
Trial outcomes
Primary outcome
The primary clinical efficacy endpoint is based on the
Patient Assessment of Constipation-Quality of Life (PAC-
QOL) questionnaire total score (analysed as a continuous
variable) in patients at 24 weeks post-surgery compared to
pre-surgery controls. The secondary clinical efficacy end-
points are based on the Patient Assessment of Constipation
Symptoms (PAC-SYM) questionnaire total score (analysed
as a continuous variable) in patients at 24 weeks post-
surgery compared to pre-surgery controls.
Secondary outcomes
All outcomes within the standardised outcome frame-
work will be analysed to compare baseline values with
values at 24 and 48 weeks post-surgery follow up. When
further follow-up data are obtained (time permitting)
these will also be reported at the later time points of 60
and 72 weeks. The outcomes are:
 Response to treatment defined as a 1-point (or
greater) reduction in the PAC-QOL score [74, 75].
 PAC-QOL: individual domains and total score
(as continuous variables).
 PAC-SYM score: individual domains and total score
(as continuous variables).
 A 2-week patient diary (for 2 weeks prior to each
assessment) to record bowel frequency and whether
each evacuation was “spontaneous (no use of laxatives)
and/or complete”; a journal will also capture
concurrent medication, health contacts, time away
from normal activities (including work) since the
patient’s last visit.
 Generic QOL assessment: EuroQol Health Outcome
measure (EQ-5D)-5L descriptive system and EQ-
visual analogue scale (VAS) [76]. Note: the EQ-VAS
has SD of approximately 30 points: a 10% difference
in VAS deemed clinically significant can be detected
with the large sample sizes proposed.
 Patient Health Questionnaire-9 (PHQ-9) [58, 59].
 Generalized anxiety disorder questionnaire (GAD7) [60].
 Global patient satisfaction/improvement score
(VAS) and whether they would recommend LVMR
to other patients.
 Potentially modifiable cognitive and behavioural
psychological variables shown to predict onset and
perpetuation of other functional bowel symptoms:
negative perfectionism [71], avoidant and “‘all or
nothing” behaviour subscales of the behavioural
response to illness questionnaire (CC-BRQ) [77],
and brief illness perception questionnaire (BIPQ)
(CC) [78].
 St Marks Incontinence score (for concurrent
symptoms) [79].
 Baseline brief sexual function questionnaire
(Pelvic Organ Prolapse/Urinary Incontinence Sexual
Questionnaire (PISQ-12) in women [80] and Male
Sexual Health Questionnaire (MSHQ)-EjD Short
Form in men [81]).
Specific adverse events and surgery-specific data
Data will be collected on:
 Perioperative findings, e.g. scarring, adhesions, tissue
laxity, pelvic depth, ovarian or uterine pathology
 Procedural data: duration of surgery, blood loss,
approach (laparoscopic vs. conversion to open), type
of mesh and sutures (make, diameter, number)
 Length of post-operative stay
 Re-admission at 30 days
 Complications: 30-day morbidity and mortality
 Specific outcomes, e.g. dyspareunia and sexual
function, pelvic pain, urinary dysfunction, new onset
of faecal incontinence or early mesh complications
(displacement, erosion, infection)
 Early clinical recurrence of structural defect
e.g. prolapse or rectocele based on rectal
examination with/without adjunctive investigations
(as clinically indicated)
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Study setting
The study setting is in specialist centres across the UK
with surgical expertise in LVMR; approximately 10 NHS
Trusts will recruit patients into the study. Eligibility of
the surgeons is based on having previously performed a
minimum of 50 LVMR and undergoing independent
assessment of adherence to the defined LVMR proced-
ural sequences.
Recruitment
Patients attending colorectal surgical services for
constipation will be eligible for recruitment and
assessed against the eligibility criteria. Such patients
will mainly include referrals from secondary care.
These will be identified and invited for eligibility
assessment by outpatient teams. Some patients may
have progressed through the earlier CapaCiTY01
and/or CapaCiTY02.
Inclusion criteria
The inclusion criteria are:
 Age 18–70 years
 Patient self-reported problematic constipation
 Symptom onset more than 6 months prior to
recruitment
 Symptoms that meet the American College of
Gastroenterology definition of constipation [82]
 Constipation that has not responded to treatment to
a minimum basic standard (NHS Map of Medicine
2012 (http://mapofmedicine.com/care-pathway-
content-update-publication/)), lifestyle and dietary
measures and ≥2 laxatives or prokinetics tried (no
time requirement) (see Additional file 4)
 Ability to understand written and spoken English
(due to questionnaire validity).
 Ability and willingness to give informed consent
 Failure of non-surgical interventions (minimum of
nurse-led behavioural therapy).
 Internal rectal prolapse as determined by clinical
examination and INVEST, fulfilling the two
following diagnostic criteria
1. Intra-anal or intra-rectal intussusception with/
without other dynamic pelvic-floor abnormalities
(e.g. rectocele, enterocele, perineal descent)
2. Deemed to be obstructing on defecating proctogram,
i.e. trapping contrast and/or associated with
protracted or incomplete contrast evacuation using
normal ranges [54] (by expert review)
Exclusion criteria
The study interventions necessitate the exclusion of major
causes of secondary constipation. In detail:
 Significant organic colonic disease (red-flag
symptoms, e.g. rectal bleeding previously
investigated); inflammatory bowel diseases;
megacolon or megarectum (if diagnosed beforehand
(the study will provide a useful estimate of the
prevalence of such cases in referral practice)); severe
diverticulosis/stricture/birth defects deemed to
contribute to symptoms (incidental diverticulosis if
known is not an exclusion)
 Major colorectal resectional surgery
 Current overt pelvic organ prolapse (bladder, uterus)
or disease requiring obvious surgical intervention
other than LVMR
 Previous rectopexy
 Sacral nerve stimulation (SNS) in situ
 Rectal impaction (as defined by digital and abdominal
examination: these form part of the NHS Map of
Medicine basic standard) (http://mapofmedicine.com/
care-pathway-content-update-publication/)
 Significant neurological disease deemed to be
causative, e.g. Parkinson’s, spinal injury, multiple
sclerosis, diabetic neuropathy (not uncomplicated
diabetes alone)
 Significant connective tissue disease, e.g.
scleroderma, systemic sclerosis and systemic lupus
erythematosus (not hypermobility alone)
 Significant medical comorbidities and activity of
daily living impairment (based on Barthel index ≤11
in apparently frail patients)
 Major active psychiatric diagnosis, e.g.
schizophrenia, major depressive illness and mania
 Chronic regular opioid use (at least once daily use),
where this is deemed to be the cause of constipation
based on temporal association of symptoms with
onset of therapy
 Pregnancy or intention to become pregnant during
study period
 Known severe intra-abdominal adhesions
Study procedures
INVEST radio-physiological investigations
Participants will have undergone standard (clinically rou-
tine) investigations to determine eligibility for surgery.
However, some patients may have missed specific tests
that are required to meet the INVEST standard of the
overall programme (or not had tests conducted in last 12
months). In such cases, individual missing investigations
will be performed to meet the standard below, with the
exception of whole-gut transit studies. In order to avoid
unnecessary repeated radiation, whole-gut transit studies
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performed in the last 12 months (even if using a different
marker protocol) may be carried forward if a clear diagno-
sis of either delayed or normal whole-gut transit time has
been confirmed.
Routine NHS practice (10-day NHS rule) will apply in
respect of women between menarche and menopause.
Participants who may potentially be pregnant will have a
serum or urine pregnancy test performed as per routine
care.
INVEST includes:
a) Anorectal manometry using high-resolution
methods [83–85] to determine defined abnormalities
of rectoanal pressure gradient during simulated
evacuation [36, 86, 87].
b) Balloon sensory testing using standardised
methods [88, 89] (2 ml air per second to
maximum 360 ml) to determine volume inflated
to first constant sensation, defaecatory desire and
maximum tolerated volumes. Rectal hyposensation
and hypersensation defined in accord to gender-
specific normative data on 91 healthy adults [90].
The rectoanal inhibitory reflex will also be elicited
by 50 ml rapid inflation (if necessary in 50 ml
aliquots up to 150 ml).
c) Fixed volume (50 ml) water-filled rectal balloon
expulsion test [36, 86, 91, 92] in the seated position
on a commode. Abnormal expulsion is defined as
abnormal if failure to expel within 1.0 minute of
effort for men and 1.5 minutes for women [93].
d) Whole-gut transit study using serial (different-
shaped) radiopaque markers over 3 days with single
plain radiograph at 120 hours [77, 94].
e) Fluoroscopic evacuation proctography using rectal
installation of barium porridge to defaecatory desire
threshold (or maximum 300 ml) and evacuation on
a radiolucent commode [54, 83–85, 95] with pre-
opacification of the small bowel (for enterocele).
Radiation dose, proportion of contrast evacuated
and time taken will be recorded, as well as
“functional” (i.e. pelvic-floor dyssynergia) and
“structural” features deemed obstructive to
defaecation (e.g. rectocele, enterocele and
intussusception) [36, 90].
Participants will be given the results of investigations
by the physiologist or radiologist.
Laboratory assessments
Serum or urine pregnancy testing will be performed
by local NHS biochemistry laboratories as per stand-
ard NHS policy prior to radiological and surgical
procedures.
Pelvic-floor MDT confirmation
As part of the whole CapaCiTY programme, a national
MDT has been convened to develop a standard set of
criteria for surgical eligibility to be used by local MDTs.
These criteria have been coalesced into a trial case
report form (CRF) that will be used to validate eligibility
for each patient before randomisation.
Randomisation procedures
Randomisation will be delivered following recruitment
(after full eligibility and all baseline assessments). Ran-
domisation will be stratified by sex and female partici-
pants further stratified by centre. The Pragmatic Clinical
Trials Unit (PCTU) has developed a validated online
randomisation system, which will be accessed by suitably
trained and delegated researchers at recruiting sites and
will follow the PCTU approved standard operating
procedure (SOP) for the study.
Blinding
Patients and clinicians are necessarily aware of allocation
to different waiting times. For quantitative analysis, an
analysis plan will be developed and signed off by investi-
gators and statisticians who are blind to allocation status
and index intervention. No quantitative analysis will be
undertaken until the analysis plan is signed off.
Study interventions
Laparoscopic ventral mesh rectopexy (LVMR)
(see Additional file 5)
Participants will attend for surgery at their allocated time
with admissions procedures as per routine clinical care
with normal preparation, e.g. bowel cleansing. Periopera-
tive care will proceed with normal adjuncts (informed
NHS consent, World Health Organization (WHO)
surgical checklist, appropriate broad spectrum antibiotic
prophylaxis, venous thromboembolism (VTE) prevention,
patient warming and urinary catheter insertion). Surgery
can be performed as a day-case procedure within an en-
hanced recovery programme [96], although most patients
will have an overnight stay. Consent will include discus-
sion of the risks of conversion to open surgery and specific
complications listed below. A phosphate enema or similar
(optional) may be used to clear the rectum.
The exact surgical technique will be surgeon-specific
(based on individual preference) but in accord with
expert guidance [73] and training. All participating
surgeons will require sign-off by a delegated surgical
team provided by the Pelvic Floor Section of the Associ-
ation of Coloproctology. Where required, preceptorship
will be provided to meet sign-off requirements (at the
time of writing, all participating surgeons are experts in
this technique).
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In brief, after positioning the patient (modified lithotomy
position on a non-slip mat) and port-site insertion (using
standard equipment and technique), the rectosigmoid junc-
tion is retracted to the left and a peritoneal incision is made
over the right side of the sacral promontory and extended
in an inverted J-form along the rectum and over the dee-
pest part of the pouch of Douglas. Special care is taken not
to damage the right hypogastric nerve. Denonvillier’s fascia
is incised and (in women) the rectovaginal septum is
broadly opened. Limited rectal mobilization and lateral dis-
section is performed as required to expose the distal rectum
and pelvic floor. A strip of trimmed mesh (biologic or syn-
thetic) is inserted. Using non-absorbable or slowly absorb-
able sutures (polydioxanone (PDS) is recommended), the
mesh is sutured to the ventral aspect of the distal rectum
and further fixed to the lateral seromuscular borders of the
rectum proximal and distal to the incised pouch of Douglas
+/- pelvic floor. The mesh is fixed upon the sacral promon-
tory using either sutures or an endofascia stapler. Limited
traction is exerted on the rectum as required to obliterate
the intussusception +/- rectocele. If deemed necessary, the
posterior vaginal fornix may be elevated and sutured to the
anterior aspect of the mesh; this allows closure of the recto-
vaginal septum and correction of a mid-compartment
prolapse, if present. The lateral borders of the incised peri-
toneum are then closed over the mesh. This elevates the
new pouch of Douglas over the colpopexy and completely
covers the mesh with peritoneum. No drain is usually re-
quired. Ports should be closed directly (endoclose for lateral
ports) owing to the high risk of early and late port site
hernias in this group of patients with potential connective
tissue laxity.
Post-operative management will be as per routine clin-
ical care. This is usually an overnight hospital stay
followed by urinary catheter removal, mobilisation and
discharge. Post-operative laxatives use is standardised to
a weaning course of Movicol/Laxido three times daily
(TDS) immediately post-operative for 1 day, then re-
duced according to ease of bowel movements. Medica-
tion will be post-operatively recorded on a drug chart by
the anaesthetists. This prevents post-operative constipa-
tion from immobility, narcotics and general anaesthesia,
which if left untreated may cause painful straining on
the mesh and thus protracts in the sacral promontory
periosteum, potentially leading to readmission. The sur-
geon should aim to discharge patients 1 day post-
operative. Length of stay will, however, be determined by
clinical evaluation and may be longer if required. Quality
control of LVMR procedures will be conducted accord-
ing to expert panel review, as per the relative SOP.
LVMR 30-day follow up
Clinical recurrence of rectal prolapse will be determined
based on physical examination. Morbidity and mortality
data will be collected, in addition to treatment of any
complications arising from LVMR surgery. The 30-day
readmission rates will also be recorded. A CRF will be
used to capture intra-operative and post-operative data
(see surgery-specific outcomes).
Concomitant medications
It is inevitable that participants will seek recourse to laxa-
tives and other dietary supplements during the course of
the programme. Experience shows that complete prohib-
ition can lead to unreported laxative use, which might
confound findings. Although we will strongly discourage
ad libitum medication usage and specify a defined break-
through regimen, we will record co-treatment with suffi-
cient fidelity and integrity to enable use as covariates in
analyses using a specific diary for this purpose. A con-
comitant medications list including a shortlist of contribu-
tory or confounding medications will be used for filtering
on data entry.
Schedule of assessment (see Fig. 1)
Visit 0 - Pre-screening: eligibility assessment
A suitably trained and delegated local researcher will
screen for basic eligibility within outpatient clinics or by
phone (or later face-to-face interview based on patient
choice) on the basis of a simplified inclusion/exclusion
criteria proforma, and listed for LVMR (in some cases/
NHS settings based on preliminary MDT review). Partic-
ipants will be recorded on a screening log and each will
be allocated a sequential study number. Eligible partici-
pants will be provided with adequate explanation of the
aims, methods, anticipated benefits and risks of the
study and will take away or be posted an invitation letter
and patient information sheet (PIS). Patients will be
given at least 24 hours to consider participation.
The study screening number will be allocated as follows:
– Study code 03
– Site code – 3-letter code for each site
– Participant code – 4-digit code given consecutively
and attributed at each site
For example, the first participant screened at Bart’s
Health Trust would be assigned the code 03-BLT-0001.
If they were then recruited to the study, they would
retain this number.
Visit 1 - consent, screening, and baseline assessments
Visit 1 will be conducted face-to-face in the clinic or pri-
vate research environment. Following a detailed discus-
sion about the trial and review of the PIS, patients who
are basically eligible and who agree to participate will
complete written informed consent, followed by screen-
ing and confirmation of eligibility for randomisation by
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obtaining structured medical and surgical history and
review of findings on physical examination. There-
after, additional baseline outcome assessments will be
conducted. These include several key validated assess-
ments that profile patients for important characteris-
tics informing disease pathophysiology and important
potential predictors of treatment response. All have
been selected on the basis of trade-off between ad-
equate detail and achievable brevity. These instru-
ments will be coalesced into a single booklet (he
design and presentation have been optimised by pa-
tient representatives).
Screening/confirmation of eligibility Screening and
confirmation of eligibility will be performed as follows:
– Structured medical and surgical history obtained by
interview, including medication usage
– Clinical examination findings (carried forward if
performed previously within the last 3 months):
standardised examination of the perineum/anus/
rectum/vagina including POP-Q assessment of
rectocele
– Review of clinical radio-physiological investigations
(some further tests may be required to meet
INVEST standard)
– Final review by pelvic floor MDT (as NHS England
draft recommendation) to confirm appropriateness
for surgery
Standardised outcome framework The standardized
outcome framework will comprise:
– PAC-QOL, PAC-SYM, EQ-5D-5L and EQVAS,
PHQ9, GAD7, CC-BRQ, BIPQ-CC, St Marks
Incontinence score, PISQ-12 in women and
MSHQ-EjD Short Form in men)
– Baseline 2-week patient bowel diary and health
economics journal will be given
Other baseline-only assessments Other baseline-only
assessments comprise:
– Constipation (2006) and IBS (2006) modules of the
Rome III questionnaire
– Cleveland Clinic constipation questionnaire [97]
– Brief, chronic pain, autonomic and joint
hypermobility assessments
Randomisation will be performed only once full eligi-
bility has been confirmed and all baseline assessments
taken (which may require INVEST). Urinary pregnancy
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) diagram. MDT Multidisciplinary Decision Team, IBSQ Irritable
Bowel Syndrome Questionnaire, LVMR Laparoscopic Ventral Mesh Rectopexy, PAC-QOL Patient Assessment of Constipation Quality of Life
questionnaire, PAC-SYM Patient Assessment of Constipation Symptoms Questionnaire, EQ-5D EuroQol Health Outcome measure, EQVAS EuroQol
visual analogue scale, PHQ-9 Patient Health Questionnaire -9, GAD7 Generalized Anxiety Disorder Questionnaire, CC chronic constipation, BIPQ
Brief Illness Perception Questionnaire, AE adverse events, ConMeds concomitant medications, V visit, POPQ Pelvic Organ Prolapse Quantification
System, Rome IIIQ constipation questionnaire based on the Rome III criteria, CC-BRQ Behavioural Response to illness Questionnaire
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testing will be made available to women of child-bearing
potential at eligibility assessment and advice will be
given to all women on the need to prevent pregnancy
during the study intervention period.
Visit 2 - run-in for surgical interventions
Participants will be randomized (at visit 1) to three arms
with different lengths of delay before surgery. In all arms
there will be a period of 4 weeks post-eligibility to arrange
the logistics of surgery (T–4w to T0) and ensure that pa-
tients have returned to their normal life routine after vari-
ous assessments. Subsequently, LVMR will be performed at
T0 in group I (visit 2); T12 (12 weeks) in group II (visit 3)
and T24 (24 weeks) in group III (visit 4).
Visit 2–8 - follow-up outcome assessments
All patients will complete the standardised outcome frame-
work (inclusive of PAC-QOL and PAC-SYM) question-
naires at T–4, T0 and 12, 24, 36, 48, 60 and 72 weeks post
run-in (see Additional file 2). This ensures that 24-week
and 48-week post-surgery follow-up data on the primary
and secondary outcomes are collected in all patients, whilst
maintaining blinding of group allocation. Thereafter, par-
ticipants will leave the study and return to “routine clinical
care” as determined within their local NHS institution.
During the first 24 weeks post-surgery patients will be
quarantined from further intervention, excepting emer-
gency interventions (e.g. for complications).
Participant withdrawal (including data collection/retention
for withdrawn participants)
Individual participants will be able to drop out at any
time during either the treatment or follow up. Data will
be retained for intent-to-treat analysis from all partic-
ipants after the point of consent and recruitment as
outlined in the PIS:
a) Withdrawal from treatment criteria (no further
interventions but follow up data collected){ participants
will be withdrawn from the study interventions if they
develop any of the following exclusion criteria:
– Becomes pregnant or intends to become pregnant
(only in baseline and intervention phases);
– Subsequently diagnosed with proven cause of
secondary constipation e.g. Parkinson’s disease or
bowel obstruction;
– Develops significant inter-current illness precluding
participation;
– Develops acute psychological problem causing
safety concern;
– Elective withdrawal.
b) Loss to follow up (no further interventions or follow
up data collected): participants may be withdrawn
from the trial if:
– They become lost to follow up (LTF) after at least
three failed attempts by research staff to make
contact via two different methods (e.g. phone
and letter);
– Participant choses to withdraw and does not wish
to participate in follow-up data collection;
– Participant dies or has significant incapacity
making follow-up data collection impossible.
End-of-study definition
The end of study is defined as the last patient last visit
(LPLV). The sponsor, Research Ethics Committee (REC)
and local Research and Development (R&D) depart-
ments will be informed of the end of study and site
closure and archiving procedures will be initiated.
Criteria for early termination
If the Data Monitoring and Ethics Committee (DMEC),
PSC, REC or sponsor determine it is within the best inter-
ests of the participants or trial to terminate the study,
written notification will be given to the CI. This may be
due to, but not limited to; serious safety concerns, serious
breaches, acts of fraud, critical findings or persistent non-
compliance that negatively affects patient safety or data
integrity. If the study is terminated, participants will be
returned to the NHS normal follow up and routine care.
Data management
The data collected for the trial will be a mixture of
routinely collected data, verifiable against the medical re-
cords and patient-reported outcome measures (PROMs)
or questionnaire data, collected directly in the CRF.
Each recruiting site will be required to keep accurate
and verifiable source notes in the medical record rele-
vant to each study participant’s inclusion and continued
participation in the study. Data will be collected, trans-
ferred and stored in accordance with Good Clinical
Practice (GCP) guidelines and data protection require-
ments. The PCTU SOPs and study data management
plan will define the exact process of data collection,
transfer and storage and control of study data.
All patient identifiable data, such as consent forms,
screening and identification logs will be stored in the
investigator site files in secure locked cabinets and/or
offices, accessible only to delegated members of the study
team. Secure methods of data transfer will be used to re-
turn CRFs to the coordinating site for centralized data
entry, monitoring, quality control and compliance. A copy
of the CRF will be held at the site in accordance with GCP.
A secure online “OpenClinica” trial database will be
provided by the PCTU to enable remote data entry of
CRFs at sites where this is feasible. This database will
provide built-in data validation checks with quality con-
trol checks performed by checking a predefined
Grossi et al. Trials  (2018) 19:90 Page 10 of 19
percentage of CRF data against data entered into the
database. In addition, on-site monitoring will enable
source document verification of records.
The full data set will be collected face to face wherever
possible to maximise completeness of data. However, to
minimise bias, where possible, a blinded researcher will
collect outcome data. Alternatively, the participant will
enter outcome data directly into the e-CRF portal for
patient-reported outcomes (REDCAP). An automated e-
mail reminder will be sent to participants to remind
them to complete the questionnaires and diaries every 12
weeks. Telephone or postal follow up will be permitted if
necessary. At least three attempts via two different methods
(e.g. phone and letter) will be made by research staff to
make contact and collect follow-up data, after which
the participant may be considered LTF if appropriate
(see criteria for withdrawal).
Confidentiality
Information related to participants will be kept confi-
dential and managed in accordance with the Data Pro-
tection Act, NHS Caldecott Principles, The Research
Governance Framework for Health and Social Care and
the conditions of REC approval.
Identifiable information to be collected from the
participants includes full name, date of birth (DOB),
hospital number and contact details at screening. This
information will be used to contact participants but will
not leave the study site without prior consent. All CRFs
will be pseudonymised. The participant’s GP will be in-
formed of their participation in the study, but they may
opt out at the time of consent.
The trial data will be made available to suitably qualified
members of the research team, study monitors and audi-
tors, the REC and regulatory authorities as far as required
by law. The participants will not by identifiable with
regards to any future publications relating to this study.
Record retention and archiving
When the research trial is complete, it is a requirement
of the Research Governance Framework and Sponsor
Policy that the records are kept for a further 20 years.
For trials involving Barts Health Trust patients, under-
taken by Trust staff, or sponsored by BH or Queen
Mary, University of London (QMUL), the approved
repository for long-term storage of local records is the
Trust Modern Records Centre.
Each site will be required to archive local site files and
patient identifiable information such as consent forms
and screening logs for a period of 20 years. At the end
of the 20 year retention period, the Records Manage-
ment team will alert R&D that the records are due for
disposal. The chief investigator (CI) and sponsor will be
informed and the full agreement of everyone concerned
will be obtained before any records are destroyed.
Statistical considerations
Sample size
The sample size has been calculated using the primary
clinical outcome, a change in mean PAC-QOL score
[74]. This widely used, psychometrically robust measure
of overall treatment response with concurrent validity
for patient global ratings of success has been used in
previous trials of behavioural therapies and surgical trials
[52] (including trials of LVMR) in CC [75]. For a chronic
condition such as CC, a difference of 1.0 point in the
primary outcome (score range = 1–4) can be considered
clinically important and also the notional minimum re-
quired to justify the cost and invasive nature of LVMR,
or of a more complex and expensive treatment.
Previous trials have shown a 1-point decrease in PAC-
QOL from pre-operative to 48 weeks (1 year) post-surgery
[52]. Using a stepped-wedge design, we hypothesize that
PAC-QOL score at any time point during follow up will
be approximately 1.0 point lower than in participants pre-
operatively.
Sample size was calculated by simulation using the
simsam package in Stata [98]. We assumed PAC-QOL
follows a normal distribution over all time points with a
standard deviation of 1.5 and with correlation between
repeated assessments equal to 0.5.
Simulation shows that detection of a 1.0-point difference
in 6-month PAC-QOL, with 95% power (purposely chosen
to reflect the magnitude and risk of the intervention) at
the 5% significance level, requires 34 participants in each
of the three arms. Allowing for a 10% loss to follow up, a
sample size of 38 is needed per arm (i.e. a total sample size
of 114 patients across the three arms). Should the correl-
ation between repeated assessments be lower than 0.5, a
sample size of 114 will still provide at least 90% power for
the study. This was calculated using the same simulation
procedure with correlations of 0.3 and 0.1.
Methods of analysis
Clinical outcomes
Primary objective Primary outcome
PAC-QOL scores at the time-points T0, T12, T24,
T36 and T48 weeks in the three arms will be ana-
lysed using a mixed linear regression model, with ran-
dom effects for participants and a fixed effect of time
since randomisation (potentially considering a random
effect for time as well to relax the assumption of
same time trend for each participant) to estimate
mean differences between PAC-QOL score before and
after LVMR. The comparison of primary interest is
between the score at 24 weeks after surgery and the
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score at baseline. Missing data will be imputed
through multiple imputation by chained equations.
Secondary outcome
PAC-SYM scores will be analysed by the same approach
as described above.
Secondary objectives All clinical outcomes derived
from the standardised outcome framework will be ana-
lysed at 0, 24, 48 and potentially 60 and 72 weeks post-
operatively. Outcomes will take the form of count (change
in number of symptom episodes), ordinal (patient’s global
impression of success) and continuous (questionnaire
scores) data. Mixed models appropriate to the outcome
data types will be fitted to estimate the treatment effect,
adjusting for baseline values, gender, and breakthrough
medication use as a potential confounder.
All participants randomized to the three groups will
be analysed according to their allocation: we would allow
for +/- 2 weeks from the scheduled intervention date.
Eventual deviations from this time buffer will be taken
into account by a modified intention-to-treat analysis.
Analysis will be performed using proprietary software
(Stata, Stata Corp. TX, USA) with p < 0.05 taken to
indicate statistical significance.
Health economic outcomes
Within-trial stochastic analysis will compare the cost/suc-
cess and cost/quality-adjusted life year (QALY) of LVMR.
Patient-level cost-effectiveness will be analysed using stand-
ard bootstrapping methods to generate cost-effectiveness
acceptability curves exploring value for money.
Cost-effectiveness models that extrapolate beyond 3–6
months duration are problematic in adult constipation,
as subsequent care and outcomes are contingent upon
subsequent care received and the underlying disease
process. However, the CapaCiTY programme as a whole
provides a unique opportunity to construct probabilistic
models exploring optimal pathways from effectiveness
and cost-effectiveness perspectives.
Since patients will (within the CapaCiTY programme)
be followed along a pathway that includes a series of
steps of care, it will be possible to construct costs and
outcomes for a range of patient pathways providing
comparative longer-term cost-effectiveness estimates.
For example, it will be possible to ask whether INVEST
or no-INVEST-led first-line care leads to lower overall
costs or improved outcomes. Patient-level data from
recruitment through the various work packages will be
used to construct pragmatic, probabilistic models to
explore optimal pathways from effectiveness and cost-
effectiveness perspectives.
Analyses from NHS and societal perspectives will be
supported by recording relevant resource use during
each work package, and a common panel of outcomes.
Adjustment for time preference will be at the socially ac-
cepted rate for cost-effectiveness analyses (currently
3.5% for costs and benefits).
Qualitative interviews
Interviews will be digitally recorded, anonymised, tran-
scribed verbatim and analysed using a pragmatic the-
matic analysis and NVivo8 software (QSR International
Ltd, Warrington, UK) for data management. Data ana-
lysis will be developed as outlined by Fereday and Muir-
Cochrane (1997) in the first instance by mapping key
concepts derived from the transcripts (“charting”) and
extracting emergent themes from the transcripts. Inde-
pendent analyses will be conducted and resulting codes
and themes will be compared and refined in discussion.
Emergent themes, together with captured observational
data, will form the basis of analytical interpretation.
Ethical considerations
General
The study will be carried out in accordance with the eth-
ical principles in the Research Governance Framework
for Health and Social Care, Second Edition, 2005 and its
subsequent amendments and applicable legal and regula-
tory requirements.
CapaCiTY study 3 is the last of the three trials in the
CapaCiTY Programme, all of which have been reviewed by
the London – City and East REC. Within the programme,
the three studies have separate protocols and patient infor-
mation sheets to be consented separately as if they were
distinct entities. This is necessary to limit patient informa-
tion, which would otherwise be over-burdensome. We
have discussed the use of sequential consent forms within
one pragmatic enriched design with Dr Art Tucker,
national ethics advisor and Chair of the London – City and
East REC, which confirms this will be practicable.
Specific
The protocol has been reviewed by Professor Richard
Ashcroft, Professor of Medical Ethics and Law at QMUL.
Important considerations that have informed pragmatic
design include:
a) Wait-list controlled design: a waiting list control
group serves the purpose of providing an untreated
comparison for the active treatment group, while at
the same time allowing the wait-listed participants
an opportunity to obtain the intervention at a later
date. In keeping with the basic ethical tenets of this
design [99], the average wait will be shorter than
that for routine services. This is achieved by
randomising patients to receive urgent (4 weeks)
or routine intervention as opposed to all having
routine status as would be normal NHS clinical
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care. Current waiting times at most included
centres are approximately 3–6 months for surgery,
whereas the mean waiting time in the study will be 3
months. Survey evidence from 100 patients indicates
that for a chronic condition such as CC, patients are
prepared to accept a randomization strategy that
allocates them to a one in three chance of waiting up
to 24 weeks for surgical treatment;
b) Limitation of intimate examinations to one time point
(not repeated if performed before recruitment);
c) Timings of outcomes: within the standardised
outcome framework, outcomes will be undertaken at
fixed intervals of 12 weeks before and after the
intervention to 48 weeks follow up within the
stepped-wedge study and thereafter in 12-week
intervals within the cohort assessments up to 72
weeks. For a period of 24 weeks of follow up
post-surgery, patients will not progress to further
therapies, thus preventing outcome “contamination”.
This “quarantine” period from major therapy
progression is required to give a reasonable clinical
impression of outcome. This delay is akin to that in
usual NHS care during which general supportive
care will be provided while further interventions are
considered. Thus, this proposed “quarantine” period
to 6 months confers no disadvantage and may even
represent an acceleration of treatment progression.
Ethically, this is viewed as a reasonable trade-off for
the commitment to the research programme;
d) Recruitment and consent: study 3 represents one of
the three studies incorporated in the NIHR-funded
CapaCiTY programme. Although patients may have
moved sequentially through earlier treatments (and
therefore studies) during the programme course,
study 3 will be consented as a distinct single entity.
The investigating team has no conflicts of interest.
Safety considerations
Surgery
LVMR has a number of established specific complica-
tions in addition to the general risks of surgery. Data on
these complications are in the public domain [72] and
can be considered to be expected events. These will,
however, still be recorded for outcome reporting.
Intra-operative complications
Intra-operative complications include inadvertent injury
to other intraperitoneal viscera. These are common to
all types of laparoscopic surgery, such as:
 Bowel, ureter, bladder or vaginal injuries or
perforations
 Vascular or nerve damage
Post-operative complications
 Urinary retention (<10%)
 Urinary tract infection
 Worsening of, or de novo urinary incontinence
 Port site complications (early or late port site hernia;
bleeding or wound infection)
 Pelvic sepsis
 Pelvic pain
 Haemorrhage especially from the posterior vaginal
wall
 Vaginal or rectal perforation
 Faecal impaction (rare)
 Small bowel obstruction
 Sexual dysfunction (rare)
 Dyspareunia (uncommon) – usually resolves with
time [100]
 Osteomyelitis of the sacrum and spondylodiscitis
[101]
 Venous thromboembolism
Prosthesis-related complications
 Minor mesh complications
 Mesh infection (<3%)
 Mesh erosion (<3%)
 Mesh sinus
Minor mesh complications can be managed by local mea-
sures including suture sinus removal, mesh trimming, per-
formed endo-rectally or endo-vaginally with subsequent
healing. Major mesh complications include (1) generalised
mesh sepsis requiring mesh removal endo-rectally or trans-
abdominally or both, with or without partial or complete
rectal excision and (2) rectovaginal fistula also requir-
ing mesh removal endo-rectally or trans-abdominally
or both +/-partial or complete rectal excision.
INVEST safety considerations
Patients undergoing INVEST-guided therapy will have
two radiological procedures (whole-gut transit study and
evacuation proctography) using ionising radiation as
outlined above. The combined dose of these procedures
(~1.2mSv) is equivalent to less than 7 months annual
background radiation dose from living in the UK (this
has been recertified by Barts Health NHS Clinical
Physics Department based on doses from 20 equivalent
procedures). Further, these investigations would be car-
ried out in routine clinical practice in many centres for
patients at the same point as recruitment to this study.
Insurance and indemnity
In the event that something does go wrong and patients are
harmed during the research and this is due to someone’s
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negligence then they may have grounds for legal ac-
tion against the sponsor QMUL, but they may have
to pay their legal costs. Insurance and indemnity is
provided by the sponsor.
Safety reporting
Serious adverse events (SAEs) that are considered to be
“related” and “unexpected” are to be reported to the
sponsor within 24 hours of learning of the event and to
the REC within 15 days in line with the required time-
frame. The CI will send the Annual Progress Report to
the REC and to the sponsor.
Expected SAEs
The following SAEs are expected to occur rarely in this
patient population and will not be reported:
– Hospital admission for exacerbation of constipation
symptoms including impaction
– Hospital admission for unrelated elective surgical
procedures or accidental injury
– Prolongation of hospitalisation due to complications
from surgery
Urgent safety measures
The CI may take urgent safety measures to ensure the
safety and protection of the clinical trial subjects from
any immediate hazard to their health and safety. The
measures should be taken immediately. In this instance,
the approval of the REC prior to implementing these
safety measures is not required. However, it is the re-
sponsibility of the CI to inform the sponsor and Main
Research Ethics Committee (via telephone) of this event
immediately.
The CI has an obligation to inform both the REC in
writing within 3 days, in the form of a substantial
amendment. The sponsor (Joint Research Management
Office (JRMO) for QMUL) must be sent a copy of the
correspondence with regards to this matter.
Overview of the safety reporting responsibilities
The CI/PI has overall responsibility for oversight of phar-
macovigilance. The CI/PI has a duty to ensure that safety
monitoring and reporting is conducted in accordance with
the sponsor’s requirements (see Additional file 6).
Monitoring and auditing
Risk assessment
The PCTU quality assurance manager will conduct a study
risk assessment in collaboration with the CI. Based on the
risk assessment, an appropriate study monitoring and
auditing plan will be produced according to PCTU SOPs.
This monitoring plan will be authorised by the sponsor be-
fore implementation. Any changes to the monitoring plan
must be agreed by the PCTU QA manager and the
sponsor.
A study may be identified for audit by any method
listed below:
– A project may be identified via the risk assessment
process;
– An individual investigator or department may
request an audit;
– A project may be identified via an allegation of
research misconduct or fraud or a suspected breach
of regulations;
– Projects may be selected at random. The
Department of Health states that Trusts should be
auditing a minimum of 10% of all research projects;
– Projects may be randomly selected for audit by an
external organisation.
Internal audits may be conducted by a sponsor’s or
funder’s representative.
Quality assessment of LVMR
Monitoring and quality control will be conducted re-
motely via video submission and assessed against the
standardised LVMR protocol and assessment criteria
(see Additional file 7). Monitoring will take the form of
planned, random and triggered sessions.
Planned monitoring
All PIs must record and submit the unedited and anon-
ymised video of the LVMR performed in the first patient
enrolled in the CapaCiTY study 3. Each video will be
allocated to two peer reviewers of a three-member ex-
pert panel. Based on blinded assessment of unedited and
anonymised videos by expert review, the panel will de-
cide whether the PI is “adherent” to the standardized
technique. Any disagreement will be solved by consen-
sus after consulting a third independent expert. If
deemed “non-adherent” to the standardized technique,
the site will be notified that a step needs to be corrected.
The PI must submit the unedited and anonymised video
of the LVMR performed in the second patient enrolled
in the CapaCiTY study 3. In case of “failure” to comply
with the standardized surgical technique for LVMR or
following a second judgment of “non-adherence” to the
standardized technique, this will trigger an on-site train-
ing and monitoring session for the site. Monitoring will
continue until adherence is achieved. Otherwise a third
“non-adherence” or second “failure” judgement will
result in withdrawal of the site/PI from the study.
Random monitoring
All PIs must record and submit the unedited and anon-
ymised video of the LVMR performed in a randomly
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selected patient enrolled in the CapaCiTY study 3 (one
in five at site level). The adherence to the standardized
technique will be established by consensus as described
for the planned monitoring.
Triggered monitoring
The DMC will review the morbidity and mortality rates,
adverse and serious adverse events from all sites. Safety
concerns may trigger additional monitoring or on-site
training and mentorship visits by an expert panel. Re-
peated “non-adherence” or “failure” to comply will result
in PI and site withdrawal.
Devices and licenses
Devices
The following is a list of all devices used. None are
specific to the research itself and all are currently used
in routine clinical practice. All are European-conformity
(CE)-marked and approved for use in the UK
a) Disposable proctoscope (supplier as in local NHS
practice). This will be commonly be used as part of
clinical examination at baseline and is also used to
introduce barium paste into the rectum during
INVEST;
b) High-resolution anorectal manometry catheters and
rectal balloons for anal manometry/rectal sensory
testing: various suppliers (part of INVEST – see above);
c) Balloon catheters for the balloon expulsion test
(part of INVEST – see above);
d) Radiopaque markers for colonic transit study:
various suppliers (part of INVEST – see above);
e) Standard departmental x-ray equipment including
the radiolucent commode for the proctogram
(part of INVEST- see above);
f ) Surgical instrumentation including disposable and
reusable instruments;
g) Mesh:
– Synthetic: titanium-coated lightweight
polypropylene;
– Biologic: Strattice, Permacol;
– Mixed: biologic and synthetic;
h) Suture material: any; usually long-term absorbable
material e.g. PDS.
Licenses
Most of the questionnaire-based tools are free to use
within the public domain. The permissions/licenses to use
all instruments will be sought with finance where required:
 PAC-QOL score: MAPI registered
 PAC-SYM score: MAPI registered
 MSHQ-EjD: MAPI registered
 EQ-5D-5L: registered
No costs are associated with the following tools:
 Depression, anxiety and somatisation modules of the
Patient Health Questionnaire
 Illness perception questionnaire
 Composite Rome III/Cleveland Clinic constipation
questionnaire
 Brief, chronic pain, autonomic and joint
hypermobility
 Negative perfectionism
 Avoidant and “all or nothing” behaviour subscales of
the behavioural response to illness questionnaire
Trial management
Each participating centre will identify a site-specific PI
who will nominate a local contact for that centre (this
may be the PI). The PI and local contact will:
 Be familiar with the trial;
 Liaise with the Programme Management Group
(PMG);
 Ensure that all staff involved in the trial are
informed about the trial and have received requisite
training;
 Ensure that mechanisms for recruitment of eligible
participants, including the availability of participant
information and data collection tools, are in place;
 Monitor the effectiveness of data collection tools
and participant information and discuss the reasons
for non-recruitment with relevant staff;
 Ensure site staff collect necessary trial data and
perform quality checks;
 Notify the CI of any SAEs and serious breaches
within required timelines;
 Make data available for verification, audit and
inspection processes as necessary;
 Respond to requests for documentation and data
required for centralised monitoring;
 Ensure that the confidentiality of all information
about trial participants is respected by all persons.
Site initiation will be conducted with each site. This
will include training in the trial protocol and SOPs, such
as data collection, randomisation and taking informed
consent. Evidence of appropriate training, local ap-
provals and essential documentation will be required
before participants are enrolled at each site. Training
will be documented on training logs.
Trial committees
The project will be under the auspices of the CI and the
PCTU. The project will be overseen by a Programme
Steering Committee (PSC). The composition and respon-
sibilities of the PSC will comply with the NIHR guidance
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and PCTU SOP on Trial Oversight Committees. The role
of the PSC is to provide overall supervision of the study
on behalf of the sponsor and funder to ensure the study is
conducted in accordance with the principles of Good
Clinical Practice (GCP) and relevant regulations.
The responsibilities of the PSC will include:
 Ensuring that views of users and carers are taken
into consideration
 Advising on the trial protocol
 Advising on changes in the protocol based on
considerations of feasibility and practicability
 Assist in resolving problems brought to it by the
PMG
 Monitor the progress of the trial and adherence to
the protocol and milestones
 Consider new information of relevance from other
sources
 Consider and act on the recommendations of the
DMEC, sponsor and/or REC
 Review trial reports and papers for publication
The PSC will meet to review the protocol before the
start of the programme and then soon after the first par-
ticipants are recruited and either meet or teleconference
every 6 months thereafter throughout the lifetime of the
programme. Representatives of the trial sponsor and
funder will be invited to attend.
The PMG will meet monthly initially during study set up
and then less frequently, every 2 months. The PMG will be
responsible for day-to-day project delivery across participat-
ing centres, and will report to the PSC. The PMG will be
responsible for monitoring adherence to the study timelines
and expected recruitment rates. Regular reports will be pro-
duced to enable deviations from the project plan to be
identified and contingencies planned, discussed and exe-
cuted in a timely fashion (see Additional file 8).
The DMEC will be convened. A “Data Monitoring
Committees: Lessons, Ethics, Statistics” (DOMACLES)
charter will be adopted, and the project team will pro-
vide the DMEC with a comprehensive report, the
content of which should be agreed in advance by the
Chair of the DMEC and follow guidelines set out in the
charter. The DMEC will meet at least 4 weeks prior to
the PSC to enable recommendations to forwarded.
A constipation research advisory group (CRAG) will
be formed as part of a well-developed patient and public
involvement (PPI) strategy at QMUL (in close associ-
ation with the charity Bowel and Cancer Research). This
advisory group will comprise eight patients and two lay
members from London and Durham. This group will
have geographical diversity (north and south) and a
disease-appropriate demographic (eight women, two
men). The CRAG will review participant information
sheets, booklets, diaries and advertising/marketing mate-
rials, provide lay representation on the PSC, conduct
parallel qualitative analysis, produce lay summaries for
dissemination of results, present at local research events
and conduct patient focus groups and workshops.
Discussion
An individual-level stepped-wedge randomised trial
serves the purpose of providing an untreated compari-
son for the active treatment group, while at the same
time allowing the wait-listed participants an opportunity
to obtain the intervention at a later date. In keeping with
the basic ethical tenets of this design, the average wait-
ing time for LVMR (12 weeks) will be shorter than that
for routine services (24 weeks). We acknowledge that
availability of beds may represent a major bane for this
trial. However, we have attempted to overcome this by
allowing a 4-week run-in post-eligibility to arrange the
logistics of surgery and a 2-week tolerance interval from
the scheduled intervention date.
Trial status
Recruitment is ongoing.
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